Galecto (GLTO) Stock Price, News & Analysis

Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $4.00 to $6.62
• 50-Day Range: $3.97 to $6.70
• 52-Week Range: $3.76 to $21.06
• Volume: 622,063 shs
• Average Volume: 73,365 shs
• Market Capitalization: $6.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Galecto Stock Analysis - MarketRank™

Galecto scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Galecto has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Galecto has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Galecto are expected to grow in the coming year, from ($15.91) to ($13.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Galecto is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galecto is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galecto has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.61% of the float of Galecto has been sold short.

Short Interest Ratio / Days to Cover

Galecto has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galecto has recently decreased by 10.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galecto does not currently pay a dividend.

Dividend Growth

Galecto does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.61% of the float of Galecto has been sold short.

Short Interest Ratio / Days to Cover

Galecto has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galecto has recently decreased by 10.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: -0.14

News Sentiment

Galecto has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Galecto this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for GLTO on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Galecto insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,979.00 in company stock.

Percentage Held by Insiders

11.90% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.20% of the stock of Galecto is held by institutions.

GLTO Stock Analysis - Frequently Asked Questions

How have GLTO shares performed this year?

Galecto's stock was trading at $4.65 on January 1st, 2025. Since then, GLTO stock has increased by 5.4% and is now trading at $4.90.
View the best growth stocks for 2025 here.

How were Galecto's earnings last quarter?

Galecto, Inc. (NASDAQ:GLTO) posted its quarterly earnings data on Wednesday, March, 19th. The company reported ($5.22) EPS for the quarter, missing the consensus estimate of ($3.12) by $2.10.

When did Galecto's stock split?

Shares of Galecto reverse split before market open on Friday, August 30th 2024. The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Galecto IPO?

Galecto (GLTO) raised $86 million in an IPO on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and Kempen & Co. was co-manager.

Who are Galecto's major shareholders?

Galecto's top institutional investors include Renaissance Technologies LLC (1.14%), Squarepoint Ops LLC (0.96%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Orbimed Advisors Llc, Hans T Schambye and Lori Firmani.
View institutional ownership trends.

How do I buy shares of Galecto?

Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galecto own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galecto investors own include Medical Properties Trust (MPW), Realty Income (O), Oxford Square Capital (OXSQ), Plug Power (PLUG), AGNC Investment (AGNC), Aberdeen Total Dynamic Dividend Fund (AOD) and Abrdn Global Infrastructure Income Fund (ASGI).

Company Calendar

• Last Earnings: 3/19/2025
• Today: 3/26/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLTO
• CIK: 1800315
• Web: galecto.com
• Phone: 45-7070-5210
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +104.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($18.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,350,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -76.96%
• Return on Assets: -66.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.68
• Quick Ratio: 8.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.81 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 1,322,000
• Free Float: 1,160,000
• Market Cap: $6.48 million
• Optionable: Optionable
• Beta: 1.18